Apyx Medical Corp (APYX) presents a materially negative liquidation posture as of March 31, 2026. Under the liquidation lens, haircutted assets are insufficient to cover face-value liabilities, consistent with prior periods. Total reported assets of $63.0M haircutted: cash $31.1M at 100% = $31.1M; AR gross $13.8M (net $12.8M with $1.0M allowance) at 90% = ~$12.4M; inventory net $9.5M at 60% = $5.7M; PP&E net $2.2M at 60% = $1.3M; operating lease ROU $4.1M at 0%; intangibles/goodwill not separately tagged but OtherAssetsNoncurrent $1.9M at 0%. Approximate haircutted asset pool: ~$52M. Against this, total liabilities stand at face value of $49.9M, comprising: $37.5M long-term debt (Perceptive Credit Agreement), current liabilities $9.4M, operating lease liabilities $4.3M ($0.4M current + $3.9M noncurrent), and other noncurrent liabilities $0.3M. Equity recovery is thin or negative depending on assumption granularity; MFFAIS CLV of -$17.3M confirms deeply negative cash liquidation value. The dominant driver of negative recovery is the $37.5M Perceptive term loan, which carries a $35.3M bullet maturity in 2028, meaning the liability stack is structurally back-ended but carried at face value in any wind-down scenario. No goodwill or identifiable intangibles appear separately on the balance sheet in this filing, which limits the typical zero-haircut impairment hit. China JV (VIE) assets total $0.6M with $0.1M liabilities; the VIE assets are contractually unavailable to settle parent obligations per the filing's own disclosure. Management discloses ongoing product liability litigation with probable losses of approximately $1.6M-$1.9M (Renuvion suits filed March 2024) plus a separate $1.95M maximum exposure from earlier suits, none of which appears to be separately tagged in XBRL — these contingent liabilities are reflected in accrued liabilities but exact allocation is not disclosed. A $3.0M minimum cash covenant under the Perceptive agreement further constrains available liquidity in a distress scenario. Working capital of approximately $45.3M is positive and declined modestly from $46.8M at December 31, 2025, driven by AR growth offset by accrued liability drawdown. The filing confirms compliance with all financial covenants as of March 31, 2026. Compared to the prior filing (10-K for year ended December 31, 2025, which is the PRIOR_FILING_BODY), balance sheet structure is substantially unchanged quarter-over-quarter: debt face value unchanged at $37.5M, cash declined marginally from $31.7M, and AR grew by approximately $4M, reflecting higher Q1 2026 revenues.
▼ Community Notes